BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 19477365)

  • 1. Atenolol is dead: long live beta-blockade.
    Cockcroft JR
    J Am Coll Cardiol; 2009 Jun; 53(22):2102; author reply 2106-7. PubMed ID: 19477365
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE study.
    Olsen MH; Wachtell K; Dahlöf B; Devereux RB; Ibsen H; Kjeldsen SE; Lindholm LH; Lyle PA; Nieminen MS
    J Hum Hypertens; 2006 Jun; 20(6):460-4. PubMed ID: 16572193
    [No Abstract]   [Full Text] [Related]  

  • 3. Atenolol versus other beta-adrenergic blockers.
    Aursnes I; Osnes JB
    J Am Coll Cardiol; 2009 Jun; 53(22):2101-2; author reply 2106-7. PubMed ID: 19477363
    [No Abstract]   [Full Text] [Related]  

  • 4. Atenolol as initial antihypertensive therapy: an observational study comparing first-line agents.
    Blackburn DF; Lamb DA; Eurich DT; Johnson JA; Wilson TW; Dobson RT; Blackburn JL
    J Hypertens; 2007 Jul; 25(7):1499-505. PubMed ID: 17563574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
    Hamon M
    Lancet; 2002 Jun; 359(9324):2199-200; author reply 2203-4. PubMed ID: 12091003
    [No Abstract]   [Full Text] [Related]  

  • 6. [Therapy of hypertension in patients with atrial fibrillation. Sartan is superior to beta-blocker].
    MMW Fortschr Med; 2003 May; 145(19):53. PubMed ID: 12813983
    [No Abstract]   [Full Text] [Related]  

  • 7. Different metabolic effects of selective and nonselective beta-blockers rather than mere heart rate reduction may be the mechanisms by which beta-blockade prevents cardiovascular events.
    Fragasso G; Cera M; Margonato A
    J Am Coll Cardiol; 2009 Jun; 53(22):2105; author reply 2106-7. PubMed ID: 19477370
    [No Abstract]   [Full Text] [Related]  

  • 8. [Criticism against the atenolol meta-analysis remains].
    Forsén K
    Lakartidningen; 2005 Feb 7-13; 102(6):412, 414; discussion 414-5. PubMed ID: 15754686
    [No Abstract]   [Full Text] [Related]  

  • 9. [Does Kent Forsen possibly have a complete picture about atenolol?].
    Carlberg B; Samuelsson O; Lindholm LH
    Lakartidningen; 2005 Jan 17-23; 102(3):151-2. PubMed ID: 15712744
    [No Abstract]   [Full Text] [Related]  

  • 10. Beta-blockers and hypertension.
    Cruickshank JM
    J Am Coll Cardiol; 2009 Jun; 53(22):2105-6; author reply 2106-7. PubMed ID: 19477369
    [No Abstract]   [Full Text] [Related]  

  • 11. [To protect the hypertensive patient from complications. Blood pressure lowering is not equal to blood pressure lowering].
    MMW Fortschr Med; 2003 Nov; 145(45):51. PubMed ID: 14712789
    [No Abstract]   [Full Text] [Related]  

  • 12. [Noticeable meta-analysis of atenolol does not cover all aspects].
    Forsén K
    Lakartidningen; 2005 Jan 3-16; 102(1-2):61-3. PubMed ID: 15707110
    [No Abstract]   [Full Text] [Related]  

  • 13. [Cardiac protection of atenolol: want of proof].
    Shi ZW
    Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(13):928-30. PubMed ID: 16029536
    [No Abstract]   [Full Text] [Related]  

  • 14. The LIFE Trial in 2004.
    Beevers DG
    J Hum Hypertens; 2004 Jun; 18(6):365. PubMed ID: 15153931
    [No Abstract]   [Full Text] [Related]  

  • 15. [The double messages about atenolol must be an issue for the SBU board].
    Werkö L; Enkvist C
    Lakartidningen; 2004 Dec; 101(49):4038, 4041; discussion 4041-2, 4045. PubMed ID: 15633347
    [No Abstract]   [Full Text] [Related]  

  • 16. [Angiotensin 1-antagonists: primary therapeutic option in arterial hypertension, too].
    Traut
    Dtsch Med Wochenschr; 2003 Jan; 128(4):161; discussion 161-2. PubMed ID: 12589590
    [No Abstract]   [Full Text] [Related]  

  • 17. Beta-blocker-induced heart rate lowering, cardioprotection, and hypertension.
    Khan SS
    J Am Coll Cardiol; 2009 Jun; 53(22):2104-5; author reply 2106-7. PubMed ID: 19477368
    [No Abstract]   [Full Text] [Related]  

  • 18. [Kidney protection leads to heart protection, too].
    MMW Fortschr Med; 2006 Aug; 148(33-34):57. PubMed ID: 16981393
    [No Abstract]   [Full Text] [Related]  

  • 19. Atenolol and cardiovascular risk: an issue close to the heart.
    Wilkinson IB; McEniery CM; Cockcroft JR
    Lancet; 2006 Feb; 367(9511):627-9. PubMed ID: 16503444
    [No Abstract]   [Full Text] [Related]  

  • 20. [Atenolol in treatment of patients with airway obstruction].
    Chazan R
    Pol Merkur Lekarski; 1996 Dec; 1(6):428-30. PubMed ID: 9273241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.